Technology News and Research

RSS

athenahealth sign merger agreement with Anodyne Health Partners

Athenahealth, Inc., a leading provider of internet-based business services for physician practices, today announced that it has signed a definitive agreement to acquire Anodyne Health Partners, Inc., a provider of Software-as-a-Service (SaaS) business intelligence (BI) solutions for healthcare providers.

5 Oct 2009

Eleventh-hour lobbying campaigns hope to lower costs to industry

As the Senate Finance Committee finalizes its health reform proposal, medical-device makers are hoping to convince lawmakers to make one last change, The Wall Street Journal reports. "The Advanced Medical Technology Association, or AdvaMed, the trade group for the larger device manufacturers, wants [Committee Chair Max Baucus of Montana] to reduce $40 billion in fees over the next decade to $15 billion, according to people close to the negotiations. But industry was told that offer is too low.

5 Oct 2009

Costs of health bills, health care under scrutiny

"A bill to overhaul the nation's ailing health care system must avoid additional spending now, and also lower costs down the road, former Federal Reserve Chairman Alan Greenspan said Sunday," CNN reports. "Greenspan told the ABC program 'This Week' that the federal debt was already getting too big, so reforming health care must do more than achieve what politicians call revenue neutrality — bringing in as much money as it costs."

5 Oct 2009

LA BioMed granted $1.3M for investigating ESAI's KRONOS IV in correcting erectile dysfunction

Las Vegas-based Endogenous Stem Cells Activators Inc. (ESAI) announced today that it will award a $1.3 million grant to Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LABioMed) for pre-clinical studies aimed at activating penile endogenous (adult) stem cells with the company's drug, KRONOS IV.

5 Oct 2009

Sonora Medical Systems sold to Medical Imaging Holdings for $8 million

Misonix, Inc., a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, announced today that substantially all of the assets of its subsidiary, Acoustic Marketing Research, Inc., DBA Sonora Medical Systems, were sold to Medical Imaging Holdings, Inc., for $8 million in cash.

5 Oct 2009

Arrayit deploys new proteomics platform

Arrayit Corporation, a life sciences and health care technology innovator, announces that on October 1st, 2009, the company deployed its next-generation proteomics platform to customers working in the areas of proteomics and in vitro molecular diagnostics.

5 Oct 2009

ACS to establish EHR and HIE interoperability for Wyoming Department of Health

Affiliated Computer Services, Inc. (NYSE: ACS), today announced a $4 million, three-year contract to provide the State of Wyoming with powerful tools to improve care for Medicaid clients and reduce program costs.

5 Oct 2009

Baxter launches HYLENEX recombinant for pediatric rehydration at the 2009 ACEP

Baxter International Inc. today announced the commercial launch of HYLENEX recombinant (hyaluronidase human injection) for use in pediatric rehydration at the 2009 American College of Emergency Physicians (ACEP) scientific assembly (Boston). HYLENEX, an enzyme, allows fluids to be administered under the skin (subcutaneously) rather than through a vein.

From Baxter International Inc. 5 Oct 2009

Innovative health care information technology solutions to improve quality of patient care

Methodist Hospital of Arcadia, California, has launched an integrated deployment of innovative health care information technology (HIT) solutions designed to help improve the quality of patient care and deliver operational efficiencies. MedPlus®, the health care information technology subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), provided the integrated solution to help Methodist reduce the length of stay associated with patients and help realize gains in efficiency and revenue.

5 Oct 2009

Preclinical study results of AVL-181 protease inhibitor presented

Avila Therapeutics, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, pan-genotype, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181.

5 Oct 2009

New consumer At-Home Skin Typing and Analysis Kit unveiled

Reveal Sciences, LLC, a cosmetics and aesthetics innovation company pioneering breakthrough skin care diagnostics, has announced the launch of the new consumer At-Home Skin Typing and Analysis Kit.

5 Oct 2009

BronxRHIO to deploy Axolotl's health information exchange solutions

The Bronx Regional Health Information Organization today announced that it has signed an agreement with Axolotl Corp., the nationwide leader in health information exchange (HIE) solutions and services. The BronxRHIO, a not-for-profit organization established by the borough’s leading healthcare organizations, will deploy Axolotl’s Elysium® Exchange suite of solutions to enable healthcare providers to securely access and share clinical information, with a goal of reducing healthcare costs and improving the quality of patient care.

5 Oct 2009

Baptist Healthcare System deploys Mckesson's Horizon Enterprise Revenue Management solution

Kentucky-based Baptist Healthcare System plans to stay ahead of the information technology curve. When a switch was flipped on Aug. 15 at Baptist Hospital Northeast in La Grange, Ky., the health system became the first to simultaneously implement both the access and business management modules of McKesson’s Horizon Enterprise Revenue Management™ solution.

5 Oct 2009

Prednisporin is a key asset in the proposed acquisition of Fovea by Sanofi-Aventis

CombinatoRx, Incorporated, today announced that its ophthalmic collaborator, Fovea Pharmaceuticals SA, has entered into a proposed acquisition with Sanofi-Aventis. A CombinatoRx-derived combination drug candidate, Prednisporin, (FOV1101), which is a fixed dose combination of prednisolone and cyclosporine, is the most advanced product asset in the Fovea pipeline, with Phase 2b clinical studies planned for the treatment of persistent allergic conjunctivitis.

5 Oct 2009

Biochemics signs research collaboration agreement with Unilever

BioChemics, Inc. a company “enhancing drug delivery through biophysical modulation,” is pleased to announce the signing of a research collaboration agreement with Unilever, one of the world’s largest consumer goods companies, to utilize BioChemics’ proprietary topical delivery technology for the delivery of Unilever’s compounds.

5 Oct 2009

Sigma-Aldrich and Sangamo Biosciences extend license agreement for ZFP technology

Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals.

5 Oct 2009

ImThera Medical launches the aura6000 neurostimulation system for treating Obstructive Sleep Apnea

Today, at the American Academy of Otolaryngology-Head and Neck Surgery annual meeting, ImThera Medical, Inc. unveiled its new product, the aura6000™ neurostimulation system for the treatment of Obstructive Sleep Apnea (OSA).

5 Oct 2009

New technique for tracing ultra-fine particles

Limit values for fine dust emissions are based on total particle weight. It is the ultra-fine particles, however, that are particularly harmful to health. A new technique separates them by size and identifies their composition - directly where they arise.

5 Oct 2009

Jefferies expands its global Healthcare Investment Banking Group

Jefferies today announced the expansion of its global Healthcare Investment Banking Group with the hiring of five senior professionals. Henry Elphick, Tommy Erdei and Probir Rao join as Managing Directors, Gil Bar-Nahum as a Senior Vice President, and Andrew Clayton as a Vice President. Henry Elphick, Tommy Erdei and Gil Bar-Nahum are based in London, Probir Rao is based in Mumbai, and Andrew Clayton in Hong Kong.

5 Oct 2009

Positive results from Depomed's Phase 3 clinical trial of DM-1796 for postherpetic neuralgia

Depomed, Inc. today announced top-line results from a Phase 3 clinical trial demonstrating DM-1796 (also referred to as gabapentin ER) achieved a statistically significant reduction in pain associated with postherpetic neuralgia (PHN) versus placebo using the baseline observation carried forward (BOCF) method required by FDA.

5 Oct 2009

Technology News and Research

athenahealth sign merger agreement with Anodyne Health Partners

Eleventh-hour lobbying campaigns hope to lower costs to industry

Costs of health bills, health care under scrutiny

LA BioMed granted $1.3M for investigating ESAI's KRONOS IV in correcting erectile dysfunction

Sonora Medical Systems sold to Medical Imaging Holdings for $8 million

Arrayit deploys new proteomics platform

ACS to establish EHR and HIE interoperability for Wyoming Department of Health

Baxter launches HYLENEX recombinant for pediatric rehydration at the 2009 ACEP

Innovative health care information technology solutions to improve quality of patient care

Preclinical study results of AVL-181 protease inhibitor presented

New consumer At-Home Skin Typing and Analysis Kit unveiled

BronxRHIO to deploy Axolotl's health information exchange solutions

Baptist Healthcare System deploys Mckesson's Horizon Enterprise Revenue Management solution

Prednisporin is a key asset in the proposed acquisition of Fovea by Sanofi-Aventis

Biochemics signs research collaboration agreement with Unilever

Sigma-Aldrich and Sangamo Biosciences extend license agreement for ZFP technology

ImThera Medical launches the aura6000 neurostimulation system for treating Obstructive Sleep Apnea

New technique for tracing ultra-fine particles

Jefferies expands its global Healthcare Investment Banking Group

Positive results from Depomed's Phase 3 clinical trial of DM-1796 for postherpetic neuralgia

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News